Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$2.71 – $3.10
Volume6,018
Market cap$5M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.91M
Price / earnings
—
Price / book
0.08×
Price / sales
4.96×
EV / sales
6.36×
EV / EBITDA
-0.81×
Profitability
Earnings per share
-$5.99
Return on assets
-11.21%
Return on equity
-15.34%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.15×
Current ratio
3.04×
Quick ratio
2.97×
Cash ratio
2.71×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$14.44M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SCNX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$343.64K
$56.33K
—
$590.05K
$0
$10.26K
$53.08K
$64.86K
Cost of revenue
$7.86K
$2.48K
$0
$15.43K
$0
$9.59K
$50.26K
$60.98K
Gross profit
$335.78K
$53.85K
—
$574.62K
$0
$673
$2.83K
$3.88K
Selling, general and administrative
$1.74M
$2.43M
—
$3.74M
$3.91M
$2.46M
$2.44M
$1.47M
Research and development
$1.17M
$809.75K
—
$179.1K
$864.96K
$636.3K
$1.1M
$1.41M
Total operating expenses
$3.04M
$3.56M
—
$4.94M
$5.16M
$3.57M
$4.22M
$3.5M
Operating income
-$2.7M
-$3.51M
—
-$4.36M
-$5.16M
-$3.57M
-$4.21M
-$3.5M
Interest expense
-$269.79K
-$37.02K
—
-$1.8M
-$653.49K
-$670.78K
-$1.01M
-$217.43K
Income before taxes
-$2.82M
-$3.4M
—
-$3.61M
-$6.72M
-$3.06M
-$7.34M
-$3.18M
Income taxes
$0
$0
—
$0
$0
$0
-$534.4K
$0
Net income
-$2.82M
-$3.4M
—
-$3.61M
-$6.72M
-$3.06M
-$7.16M
-$3.18M
Net income attributable to common shareholders
-$2.82M
-$3.4M
—
-$3.61M
-$6.72M
-$3.06M
-$7.16M
-$3.18M
EBITDA
-$2.13M
-$2.73M
$454.35K
-$3.34M
-$4.78M
-$3.1M
-$3.54M
-$2.88M
Basic earnings per share
-$1.75
-$2.00
—
-$4.75
-$12.00
-$8.25
-$20.62
-$33.50
Diluted earnings per share
-$1.75
-$2.00
—
-$4.75
-$12.00
-$8.25
-$18.72
-$33.50
Recent news
Company coverage with links to the original publishers.
Scienture Holdings, Inc., a specialty pharmaceutical company, announced that its President, Dr. Narasimhan Mani, will participate as a speaker and panelist at the 8th Annual Conference of The Society for the Study of Xenobiotics in India.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.